The FDA has approved Rasonque, the first RAS-targeted drug for pancreatic cancer. It arrives in a disease that has resisted almost everything medicine has thrown at it.
Pancreatic cancer has a five-year survival rate of just 13%. Symptoms are vague and appear late, there is no routine screening, and until now no targeted therapy addressed the mutation driving the disease.
In trials, Rasonque nearly doubled median survival, 13.2 months versus 6.7 months on chemotherapy, and cut the risk of death by 60%. It is also a once-daily pill rather than an IV infusion, which changes what treatment looks like day to day for patients.
The catch is the price: $477,000 a year, more than double Keytruda, the top-selling cancer drug. A CVS spokesman called Rasonque a breakthrough, then warned that the price could “severely limit” who gets access.